Zomigon

zolmitriptan

Zomigon is an oral, selective 5-hydroxytryptamine (5-HT 1B/1D) receptor agonist for acute treatment of migraine attacks with or without aura in adults. Substance zolmitriptan is one of the more recent medications designed specifically for migraine. Zomigon belongs to a family of medications called ‘triptans’.

Migraines are believed to result from nerve activity and swelling of the blood vessels in the brain. Zomigon acts at several of these sites. It works by stimulating receptors called serotonin (or 5HT) receptors that are found in the brain. A natural substance called serotonin normally acts on these receptors, causing blood vessels in the brain to narrow. Zomigon mimics this action of serotonin by directly stimulating the serotonin receptors in the brain. This narrows the blood vessels and so relieves the pain of migraine headaches.

Zomigon is specifically developed for the treatment of migraine pain. Zomigon also reduces substances in the body that can trigger headache pain, nausea, sensitivity to light and sound, and other migraine symptoms.

Zomigon should be taken as early as possible after the migraine headache has started, though it is also effective if taken at a later stage during the migraine attack. Pain relief should come in one hour with a single 2.5 mg tablet.

Single doses of 1, 2.5 and 5 mg of zolmitriptan were effective for the acute treatment of migraines in adults. In the only direct comparison of 2.5 and 5 mg, there was little added benefit from the larger dose but side effects are generally increased at 5 mg. If the headache returns, the dose may be repeated after 2 hours, not to exceed 10 mg within a 24 hour period.

Zomigon is generally well tolerated. Most adverse reactions were mild and transient and did not lead to long-lasting effects. Side effects that may occur: weakness, dizziness, dry mouth, upset stomach, pain in the neck, throat, or jaw, tingling, drowsiness, nausea. Tell your doctor about any unusual or bothersome side effect.

Zolmitriptan may increase blood pressure, it should not be used within 24 hours of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-type medication, and should not be used within two weeks of discontinuation of MAO A inhibitor therapy.

Zolmitriptan can cause serious side effects on the heart, including heart attack or stroke. Although these side effects are rare, do not use this medication if you have a history of heart disease, blood circulation problems or risk factors for coronary artery disease and if you are using any other drugs. If you have any of these conditions, you may need a dose adjustment or a special tests to safely take Zomigon. Your doctor may want to give your first dose of this medicine in a hospital or clinic setting to see if you have any serious side effects.